Inari Medical said today it closed a $27 million Series C round of financing, with funds slated to support commercialization of its FlowTriever and ClotTriever catheters designed for the treatment of venous thromboembolisms.
Irvine, Calif.-based Inari’s ClotTriever device is designed to remove blood clots from large vessels in the peripheral vasculature, while it’s FlowTriever device is designed to retrieve pulmonary embolisms.
The round was led by newly invested Gilde Healthcare and joined by all of Inari’s existing investors, including Versant Ventures and U.S. Venture Partners. Inari said that as part of the round, Gilde Healthcare’s Geoff Pardo will join the company’s board of directors.
“We are fortunate to have the support of a strong consortium of life sciences venture capital firms and would like to welcome both Gilde Healthcare as an investor in Inari and Geoff Pardo as a board member. We will use these funds to support and accelerate our commercial, clinical and technology development programs,” prez & CEO Bill Hoffman said in a prepared statement.
“There is a significant need to improve outcomes for the millions of patients suffering from VTE. We have been impressed by the Inari team, the progress they’ve made to date and their vision to transform the treatment of VTE,” Gilde Healthcare’s Pardo said in a press release.
Last April, Inari Medical touted that it its ClotRetriever thrombectomy device, approved by the FDA on February 16, had already been used in its first commercial procedure.
